Sulindac has been shown to inhibit the migration and invasion of prostate, lung, breast and colon cancer cells by inhibiting the β-Catenin, EMT, TGFβ/miR-21, SIRT1 and AKT signaling pathways (Li et al., 2012; Stein et al., 2011; Stewart et al., 2009; Cha et al., 2016; De et al., 2016; Ko et al., 2017). Here, TGFB1 is linked to colonic neoplasm.